Research
Hormonal
Inhibition of specific inflammatory signaling pathways (NF-κB and JNK) can disrupt the link between obesity and insulin resistance, suggesting these pathways are therapeutic targets.
Targeting the specific inflammatory signaling pathways (like JNK and NF-κB) that are overactive in obesity may help restore insulin sensitivity. While drugs targeting these are in development, current lifestyle interventions that reduce overall inflammation may indirectly modulate these pathways.
GoodSupportsHIGH confidence
Inhibition of inflammatory signaling by knockout of key pathways in obese mice, including components of NF-κB (24) and JNK (25) pathways... can disrupt the link between obesity and insulin resistance.
Why this rating
Based on knockout mouse studies and cited human correlations, with clinical trials mentioned as ongoing.
Source
Inflammatory mechanisms linking obesity and metabolic disease
Alan R. Saltiel et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci92035
narrative_reviewCited 2,113×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic low-grade inflammation is a causative mechanism for insulin resistance and metabolic disease in obesity, rather than merely a consequence.Good
- Obesity-induced inflammation involves a shift in adipose tissue macrophages from an anti-inflammatory M2 state to a pro-inflammatory M1 state, which secretes cytokines like TNF-α that block insulin signaling.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →